| Name | Title | Contact Details |
|---|
Bardavon Health Innovations is a proactive Workers` Compensation partner that connects all stakeholders to better manage claims. We offer work readiness solutions through rehabilitation therapy. We share a holistic analysis of the claim so America`s injured workers can achieve optimized functional outcomes and return to full-duty.
C-TASC provides products and services to support responsible management of clinical trials, clinical surveys, case/control studies, clinical registries, clinical cohort studies and laboratory studies. For over 15 years C-TASC's services group has played nearly every role in studies of all sizes. Our experienced and professional medical and biostatistical staff can provide expertise in complete study design, data collection and management and data analysis. C-TASC's software group has developed, hosted and managed Web-based clinical data management systems for dozens of studies including the recent release of our SaaS product StudyCTMS.com, an end-to-end clinical trials management system (CTMS) including electronic data capture (EDC), integrated SAS, a drag and drop form builder and many other intuitive tools. StudyCTMS.com is an affordable solution for every investigator. Our location is convenient to Washington DC, Maryland, Philadelphia, and Southern New Jersey.
Parsley Health is a new kind of healthcare service that integrates technology, nutrition, wellness and prevention into cutting-edge primary care.
CARTI is a multi-disciplinary cancer care provider with locations throughout Arkansas. Providing medical, radiation, interventional and surgical oncology, as well as diagnostic radiology, CARTI cares for more than 20,000 cancer patients each year.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.